Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shs5 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
+0.7%		$0.02
$0.00
▼
$0.23
N/AN/A63,698 shs17,749 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
$2.95M2.19N/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
$0.00
$0.01
$0.00
▼
$0.25
N/AN/A92,954 shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%+15.46%-39.96%-88.18%
Apollomics, Inc. stock logo
APLMW
Apollomics
-22.53%-7.84%+2.17%-14.55%-44.27%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
0.00%0.00%0.00%0.00%-96.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shs5 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
+0.7%		$0.02
$0.00
▼
$0.23
N/AN/A63,698 shs17,749 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
$2.95M2.19N/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
$0.00
$0.01
$0.00
▼
$0.25
N/AN/A92,954 shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%+15.46%-39.96%-88.18%
Apollomics, Inc. stock logo
APLMW
Apollomics
-22.53%-7.84%+2.17%-14.55%-44.27%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
0.00%0.00%0.00%0.00%-96.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
$6.99M0.42N/AN/AN/A∞
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest BCTXW, ALVOW, APLMW, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
2073.56 millionN/ANo Data
BriaCell Therapeutics Corp. stock logo
BCTXW
BriaCell Therapeutics
8N/AN/ANot Optionable

Recent News About These Companies

BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
January 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-patients-images-show-regression-and-resolution-of-metastasized-tumors-and-immune-activation-1035755025
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer
December 3, 2025  |  bctechnology.comB
BriaCell announces publication with preliminary Phase 1b expansion cohort data
December 2, 2025  |  msn.comhttps://www.msn.com/en-us/health/medical/briacell-announces-publication-with-preliminary-phase-1b-expansion-cohort-data/ar-AA1RuYtD
BriaCell, Receptor.AI collaborate on AI small molecular cancer therapeutics
November 20, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/briacell-receptorai-collaborate-on-ai-small-molecular-cancer-therapeutics/ar-AA1QP0l6
BriaCell’s Innovative Approach in Breast Cancer Treatment: A Study Update
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/briacell-s-innovative-approach-in-breast-cancer-treatment-a-study-update/ar-AA1Pj30t
BriaCell to present clinical biomarker data of Phase 3 Bria-IMT study
October 13, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/briacell-to-present-clinical-biomarker-data-of-phase-3-bria-imt-study/ar-AA1OnDkm
BriaCell’s Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
September 22, 2025  |  bctechnology.comB
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
July 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/briacell-subsidiary-briapro-files-patent-113000106.html
BriaCell Therapeutics Announces Closing of $15 million Public Offering
July 16, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/briacell-therapeutics-announces-closing-15-200500907.html
Bria-IMT Improves Survival in Patients With Metastatic Breast Cancer
July 15, 2025  |  curetoday.comC
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering
July 9, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/briacell-shares-slide-22-after-announcing-dilutive-public-offering/ar-AA1IgNFJ
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer - Morningstar
June 25, 2025  |  morningstar.comM
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer - Yahoo Finance
June 25, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/briacell-announces-positive-recommendation-data-113000910.html
BriaCell Therapeutics Corp. (BCTXZ) - Yahoo Finance
June 25, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/BCTXZ/news/
BCTXW BriaCell Therapeutics Corp. WT EX 022626
June 6, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/BCTXW
BriaCell’s Bria-IMT Shows Strong Survival & Benefit in Advanced Breast Cancer
June 2, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/briacell-s-bria-imt-shows-strong-survival-benefit-in-advanced-breast-cancer/ar-AA1FXseN
BriaCell Therapeutics Corp. Wt
May 10, 2025  |  barrons.comhttps://www.barrons.com/market-data/stocks/bctxz/stock-grader
BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
April 10, 2025  |  thestar.comT
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacell-s-phase-3-study-in-metastatic-breast-cancer-1034496895
BriaCell Therapeutics Reports Continued Financial Challenges
March 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/briacell-therapeutics-reports-continued-financial-challenges?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 08/10/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.01 +0.00 (+0.71%)
As of 12:22 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 08/10/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

BriaCell Therapeutics stock logo

BriaCell Therapeutics NASDAQ:BCTXW

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas